Regeneron Pharmaceuticals Inc

DelveInsight estimates the paroxysmal nocturnal hemoglobinuria market across the seven major markets was valued at approximately USD 1.5 billion in 2025 and is projected to expand at a CAGR of 7.1% through 2036, driven by novel complement-targeted therapies and rising diagnosis. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Five emerging therapies are highlighted as poised to reshape the market: Regeneron Pharmaceuticals' Pozelimab plus Cemdisiran, Novo Nordisk's Zaltenibart, also known as OMS906, NovelMed Therapeutics' Ruxoprubart, also known as NM8074, Kira Pharmaceuticals' KP104, and NovelMed Therapeutics' NM5072. Aparna Thakur, Project Manager of Forecasting and Analytics at DelveInsight, said Pozelimab is expected to generate the highest revenue in the 7MM, followed by Zaltenibart, which demonstrated strong efficacy in a Phase II study in PNH patients with suboptimal responses to ravulizumab. Regeneron has said Phase III results for the pozelimab-cemdisiran combination in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027, while Novo Nordisk gained exclusive worldwide rights to zaltenibart through an asset purchase and license agreement with Omeros Corporation announced in November 2025.

Veeva Systems announced that Regeneron and Biogen have adopted its AI-powered Vault CRM suite globally, and introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. These moves expand Veeva's AI-focused offerings across commercial and safety workflows in life sciences, reinforcing its position as a key provider of industry-specific cloud software. With a market cap of about $45.5 billion, Veeva is a large specialist in healthcare software, and these global commitments signal deeper integration of its AI tools into core biopharma operations, potentially increasing switching costs and making multi-year relationships more durable. The company plans a November 2026 rollout for Falcon Safety, and investors will watch for early adopters and quantified updates in upcoming earnings calls to gauge traction.

Regeneron Pharmaceuticals has received FDA approval for Pasatru (garetosmab) to treat adults with fibrodysplasia ossificans progressiva, a rare and severely debilitating condition, based on a positive Phase 3 trial. This approval adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream, though the FOP indication is very small, so the near-term financial impact is likely modest for the US$80.7 billion company. The approval is more significant as proof that Regeneron's R&D and antibody platforms continue to produce approved, differentiated medicines in highly targeted settings. Investors will watch how quickly Pasatru is adopted across eligible FOP centers, payer responses to pricing and access, and whether the planned Phase 3 OPTIMA 2 study in adolescents and children initiates on schedule and progresses without major setbacks.

Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally, expanding its strategic partnership with Veeva Systems. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring medicines reach eligible patients. Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron, said the move will give commercial teams a more connected platform and faster access to information for efficient decision-making. Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution.

Telix Pharmaceuticals reported first-half 2026 revenue of US$477 million, up 22% year-over-year, with adjusted EBITDA of US$52 million, up 146%. The company reaffirmed full-year revenue guidance of US$950 million to US$970 million and expects total revenue and other income to exceed US$1 billion, including a US$40 million payment from Regeneron. Telix also announced an at-the-market equity facility with Morgan Stanley and William Blair to sell American Depositary Shares on Nasdaq. Late-stage pipeline highlights include FDA alignment on the ProstACT Global Part 2 protocol for TLX591-Tx and a PDUFA goal date of September 11, 2026 for Pixclara.

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva. Approval was based on the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new HO lesions at 56 weeks compared to placebo. The recommended starting dosage is 10 mg/kg intravenously once monthly, with a possible decrease to 3 mg/kg if not tolerated. Pasatru is a fully human monoclonal antibody that blocks Activin A, a protein critical in the development of HO lesions. Regeneron plans to begin a Phase 3 trial in adolescents and children later this year, and regulatory submissions are under review in the European Union and planned in Japan.

EyePoint Pharmaceuticals announced that its investigational wet age-related macular degeneration treatment Duravyu failed to meet the primary endpoint of non-inferiority on best corrected visual acuity versus Regeneron's Eylea in the first of two pivotal phase III studies, sending its shares down 67% on Monday. The LUGANO study enrolled 211 patients and was affected by an asymmetric cohort of nine patients, about 4% of the group, who experienced vision loss of at least 15 letters that EyePoint said was unrelated to wet AMD, while no Eylea patients had similar vision loss. An ad hoc analysis excluding those nine patients showed Duravyu was non-inferior to Eylea, and the candidate achieved a 42% reduction in treatment burden, meeting the threshold for superiority. Duravyu also demonstrated favorable durability, with 54% of patients remaining supplement-free through week 56, and safety was comparable to Eylea with no cases of insert migration or severe intraocular inflammation. EyePoint expects top-line results from the identical LUCIA study in the fourth quarter of 2026 and anticipates potentially submitting a new drug application in the first half of 2027, pending those results.

Regeneron Pharmaceuticals confirmed a quarterly dividend, released second quarter and half year 2026 results, and updated on recent share repurchases. The stock last closed at $784.36, which is 5.9% below a narrative fair value of $833.31. Its current P/E of 18.1x sits just above the US Biotechs industry average of 17.3x but well below a fair ratio of 26.1x. The company's pipeline includes recent or upcoming pivotal data in immunology, oncology, genetic medicines, and obesity, supporting future revenue growth. Key risks include pressure on EYLEA from competition and pricing, as well as setbacks from fianlimab and LAG 3 trial disappointments.

CytomX Therapeutics announced second quarter 2026 financial results and a business update highlighted by progress of its lead candidate varsetatug masetecan, or Varseta-M, an EpCAM-directed antibody drug conjugate. The company expects a Phase 1 monotherapy data update in advanced colorectal cancer by the end of 2026 and plans to initiate a registrational study in the first half of 2027. Varseta-M is also being evaluated in combination with bevacizumab in late-line metastatic colorectal cancer, with a Phase 1/2 chemotherapy combination study in second-line disease set to start in the fourth quarter of 2026, and monotherapy expansion cohorts in gastric, pancreatic, and biliary tract cancers are initiating in the third quarter of 2026. CytomX expanded its Regeneron collaboration in masked bispecific immunotherapies, receiving a $37.0 million target selection payment in July 2026 for two additional programs, with total potential milestones under the collaboration now up to approximately $4.0 billion. The company reported cash, cash equivalents and investments of $330.3 million as of June 30, 2026, which does not include the $37.0 million received in July, and expects its cash runway to extend to at least the second half of 2028.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

Regeneron beat Wall Street estimates for second-quarter revenue and profit, driven by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, recorded by partner Sanofi, increased 38% to about $6 billion, surpassing estimates of $5.34 billion. Quarterly U.S. sales of the high-dose Eylea rose 52% to $596 million, while the lower-dose version faced competitive pressures. The company fully repaid the Sanofi Development Balance, which RBC Capital Markets analyst Brian Abrahams said should improve margins and make second-half numbers look much better. Quarterly revenue rose 17% to $4.29 billion, exceeding estimates of $3.82 billion, and non-GAAP adjusted profit was $14.29 per share, beating the estimate of $10.26.

Telix Pharmaceuticals reported a 21% increase in second-quarter revenue to $247 million and announced the first patient has been dosed in its Phase 3 LUTEON trial of TLX250-Tx in kidney cancer. Precision medicine revenue grew 30% to $202 million, while TMS revenue slipped 6% to $45 million. The company expects full-year 2026 revenue and other income to exceed $1 billion, with revenue tracking toward the upper end of its $950 million to $970 million guidance plus $40 million in non-refundable other income from a strategic collaboration with Regeneron. The LUTEON study is the first Phase 3 trial of a radiopharmaceutical therapy in clear cell renal cell carcinoma. Shares rose 4.05% in pre-market trading to $10.95.

Alnylam Pharmaceuticals announced the initiation of a global Phase 2 study of its investigational RNAi therapeutic mivelsiran in people with Down syndrome–associated Alzheimer's disease at the Alzheimer's Association International Conference 2026. The APPlauDS study will recruit participants with early-stage Alzheimer's across approximately 30 sites, marking the first clinical trial to evaluate an RNAi approach to reduce APP overexpression caused by trisomy 21. Alnylam also reported updated Phase 1 data in early-onset Alzheimer's disease showing no increased risk of amyloid-related imaging abnormalities and robust reductions in cerebrospinal fluid biomarkers, with mean maximum decreases of 89.9% for sAPPβ and 70.2% for Aβ42 in the highest dose group. The company completed enrollment in the Phase 2 cAPPricorn-1 study of mivelsiran in cerebral amyloid angiopathy, with initial results expected in 2028. Additionally, Alnylam presented preclinical data and the design of an ongoing Phase 1 trial for ALN‑5288, a tau-targeting RNAi therapeutic being developed in collaboration with Regeneron Pharmaceuticals.

HSBC lowered its price target on Regeneron Pharmaceuticals to $800 from $990 while maintaining a Buy rating, as part of a broader healthcare sector update. The firm highlighted therapeutics as offering attractive risk-adjusted opportunities. Separately, Regeneron announced that the FDA and EMA accepted regulatory submissions for cemdisiran as a potential treatment for generalized myasthenia gravis, with the FDA granting Priority Review and a target decision in November 2026.

Alnylam Pharmaceuticals reported $1.04 billion in net product revenues in the first quarter of 2026, a 121% year-over-year increase, driven by its four marketed drugs. Its newest drug, Amvuttra, generated $889.9 million in global sales, up 187% year-over-year, but faces competition in the ATTR-CM market from Pfizer's Vyndaqel family, which brought in $1.6 billion, and BridgeBio's Attruby, with $180.6 million in sales. Alnylam is advancing a broad pipeline to sustain long-term growth, including cemdisiran, for which Regeneron submitted a U.S. regulatory filing in April 2026 after positive phase III results in generalized myasthenia gravis, and zilebesiran, which has entered a global phase III cardiovascular outcomes study with Roche. The company is also developing mivelsiran for early-onset Alzheimer's disease and cerebral amyloid angiopathy, and nucresiran for ATTR amyloidosis, with phase III studies underway. Despite the pipeline progress, Alnylam's stock has fallen 21.4% year-to-date, and it carries a Zacks Rank #4 (Sell), with 2026 earnings estimates declining to $9.05 per share.

Regeneron Pharmaceuticals has received FDA acceptance with Priority Review for cemdisiran in generalized myasthenia gravis, and the EMA has also accepted the marketing application, aligning regulatory review on both sides of the Atlantic. Phase 3 trial data for cemdisiran were published in The Lancet, providing peer-reviewed clinical evidence. If approved, cemdisiran would be the first siRNA treatment for generalized myasthenia gravis and the only subcutaneous option with four-times-a-year dosing, potentially addressing an area of significant unmet need among the estimated 85,000 MG patients in the US and broader global prevalence. The FDA's Priority Review sets an action date in November 2026, with a planned Japan filing in early 2027. Regeneron's stock is at $654.27, down 15.7% year to date but up 20.2% over the past year.

Regeneron Pharmaceuticals stock has gained 20.2% over the past year, yet valuation checks still lean toward the shares looking inexpensive. The company trades on a price-to-earnings ratio of 15.0 times, below the biotech industry average of 17.3 times and a peer group average of 37.4 times. Simply Wall St's fair multiple suggests a P/E closer to 25.0 times, implying a sizeable gap to the current level. Regeneron screens as undervalued in all six areas assessed, pointing to the market price sitting below what these valuation tests suggest could be justified.

Eli Lilly and Regeneron Pharmaceuticals are among seven drug companies selected by the US FDA for its PreCheck Pilot Program, which aims to improve US drug manufacturing capabilities. The program offers earlier FDA engagement and a more predictable regulatory pathway for companies planning to manufacture drugs for the US market. Other selected companies include Amneal Pharmaceutical and Kyowa Kirin.

Parabilis Medicines shares closed up 58% from their $20 offer price in their June 10 IPO, a larger first-day gain than SpaceX's 19% pop. The cancer biotech is developing Helicons, helical peptides designed to enter cells and bind flat protein surfaces that are typically undruggable. Its lead asset, zolucatetide, is set to enter phase 3 trials in 2027 and has shown a 74% objective response rate in a phase 1/2 desmoid tumor study. Regeneron Pharmaceuticals signed a May 2026 collaboration providing $50 million cash, $75 million in equity, and up to $2.2 billion in milestones across five targets. Despite the early-stage promise, pivotal data is years away and the platform has only one clinical asset.

Regeneron Pharmaceuticals announced that the U.S. FDA and EMA have accepted regulatory applications for cemdisiran to treat adult anti-AChR antibody-positive generalized myasthenia gravis, with the FDA granting Priority Review and setting a target action date in November 2026. If approved, cemdisiran would be the first siRNA therapy for gMG and the only treatment administered subcutaneously just four times a year, potentially improving convenience for patients with this rare autoimmune disease. The filing extends Regeneron's complement and RNAi ambitions and adds another potential rare-disease asset to a portfolio already supported by Dupixent, EYLEA HD, and emerging oncology programs. While the Priority Review and quarterly dosing profile may reinforce the depth of the pipeline, market reaction suggests investors remain more focused on near-term growth drivers such as Dupixent indication expansions, EYLEA HD execution, and oncology launches like linvoseltamab.